With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.
5317-33-9, 500 mg of 3-bromo-5-(1H-pyrazol-4-yl)-pyridine, 850 mg of 3-(N-methylpiperazin)- propan-1-ol and 1.69 g of triphenylphosphine are dissolved in dimethylformamide. 1.28 ml of diisopropylazodicarboxylate is added to the reaction. The mixture is stirred over night at room temperature. For workup the mixture is evaporated and dichloromethane is added. The organic phase is washed with diluted HCI. The acidic aqueous phase is neutralized and extracted with dichloromethane. After drying, filtration and evaporation the product is purified by chromatography in ethyl acetate and methanol. 472 mg of 1-{3-[4-(5-bromo-pyridin-3-yl)-pyrazol-1-yl]-propyl}-4- methyl-piperazine are obtained;HPLC-MS: 1.23 min, [M+H] 366 .
As the paragraph descriping shows that 5317-33-9 is playing an increasingly important role.
Reference：
Patent; MERCK PATENT GMBH; HOELZEMANN, Guenter; DORSCH, Dieter; JONCZYK, Alfred; AMENDT, Christiane; ZENKE, Frank; WO2012/3912; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics